Five Akeso’s Drugs Included in China’s National Reimbursement List, Opening New Treatment Options

This Data Is Locked!

This area is available only to Subscribers.

Akeso, Inc. has accomplished the successful inclusion of all five self-developed innovative drugs in China's updated National Reimbursement Drug List for 2025.

This significant milestone... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?